A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects With Type 2 Diabetes and Nephropathy SONAR: Study Of Diabetic Nephropathy With Atrasentan
Latest Information Update: 08 Dec 2023
At a glance
- Drugs Atrasentan (Primary)
- Indications Diabetic nephropathies
- Focus Registrational; Therapeutic Use
- Acronyms SONAR
- Sponsors AbbVie
- 01 Dec 2023 Results of post hoc analysis assessing association between the endothelin receptor antagonist atrasentan and pain and prescription of analgesics published in the Kidney International
- 23 Mar 2023 According to a Chinook Therapeutics media release, data from this study will be presented at the ISN World Congress of Nephrology 2023 on Saturday, April 1, 2023 at 17:00-18:00 ICT.
- 27 Jul 2022 Results assessing the influence of genetic polymorphisms on atrasentan plasma exposure and pharmacodynamic effects, published in the Clinical Pharmacology and Therapeutics.